Kevin N Hascup

Dr. Kevin N Hascup

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
ESErnesto Solis
Ernesto Solis
KHKevin N Hascup
Kevin N Hascup
EHErin R Hascup
Erin R Hascup
While prevailing evidence supports that the amyloid cascade hypothesis is a key component of Alzheimer’s disease (AD) pathology, many recent studies indicate that the vascular system is also a major contributor to disease progression. Vascular dysfun

1 January 2019 in ASN Neuro
Verified
Journal Article
Open access
PDF file
CFCaleigh A. Findley
Caleigh A. Findley
ABAndrzej Bartke
Andrzej Bartke
KHKevin N Hascup
Kevin N Hascup
EHErin R. Hascup
Erin R. Hascup
Alzheimer’s disease (AD) ranks sixth on the Centers for Disease Control and Prevention Top 10 Leading Causes of Death list for 2016, and the Alzheimer’s Association attributes 60% to 80% of dementia cases as AD related. AD pathology hallmarks include accumulation of senile plaques and neurofibrillary tangles; however, evidence supports that soluble amyloid beta (Aβ), rather than insoluble plaques, may instigate synaptic failure. Soluble Aβ accumulation results in depression of long-term potentiation leading to cognitive deficits commonly characterized in AD. The mechanisms through which Aβ incites cognitive decline have been extensively explored, with a growing body of evidence pointing to modulation of the glutamatergic system. The period of glutamatergic hypoactivation observed alongside long-term potentiation depression and cognitive deficits in later disease stages may be the consequence of a preceding period of increased glutamatergic activity. This review will explore the Aβ-related changes to the tripartite glutamate synapse resulting in altered cell signaling throughout disease progression, ultimately culminating in oxidative stress, synaptic dysfunction, and neuronal loss.

22 October 2010 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
EHErin R. Hascup
Erin R. Hascup
KHKevin N Hascup
Kevin N Hascup
MSMichelle Stephens
Michelle Stephens
FPFrancois Pomerleau
Francois Pomerleau
PHPeter Huettl
Peter Huettl
GGGreg A. Gerhardt
Greg A. Gerhardt
J. Neurochem.(2010)115,1608–1620. Glutamate in the prefrontal cortex (PFC) plays a significant role in several mental illnesses, including schizophrenia, addiction and anxiety. Previous studies on PFC glutamate‐mediated function have used techniques that raise questions on the neuronal versus astrocytic origin of glutamate. The present studies used enzyme‐based microelectrode arrays to monitor second‐by‐second resting glutamate levels in the PFC of awake rats. Locally applied drugs were employed in an attempt to discriminate between the neuronal or glial components of the resting glutamate signal. Local application of tetrodotoxin (sodium channel blocker), produced a significant (∼40%) decline in resting glutamate levels. In addition significant reductions in extracellular glutamate were seen with locally applied ω‐conotoxin (MVIIC; ∼50%; calcium channel blocker), and the mGluR2/3agonist, LY379268 (∼20%), and a significant increase with the mGluR2/3antagonist LY341495 (∼40%), effects all consistent with a large neuronal contribution to the resting glutamate levels. Local administration of D,L‐threo‐β‐benzyloxyaspartate (glutamate transporter inhibitor) produced an ∼120% increase in extracellular glutamate levels, supporting that excitatory amino acid transporters, which are largely located on glia, modulate clearance of extracellular glutamate. Interestingly, local application of (S)‐4‐carboxyphenylglycine (cystine/glutamate antiporter inhibitor), produced small, non‐significant bi‐phasic changes in extracellular glutamate versus vehicle control. Finally, pre‐administration of tetrodotoxin completely blocked the glutamate response to tail pinch stress. Taken together, these results support that PFC resting glutamate levels in rats as measured by the microelectrode array technology are at least 40–50% derived from neurons. Furthermore, these data support that the impulse flow‐dependent glutamate release from a physiologically ‐evoked event is entirely neuronally derived.

1 February 2008 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KHKevin N Hascup
Kevin N Hascup
EHE. R. Hascup
E. R. Hascup
FPF. Pomerleau
F. Pomerleau
PHP. Huettl
P. Huettl
GGG. A. Gerhardt
G. A. Gerhardt
L-Glutamate (Glu) is the main excitatory neurotransmitter in the mammalian central nervous system, and it is involved in most aspects of normal brain function, including cognition, memory and learning, plasticity, and motor movement. Although microdialysis techniques have been used to study Glu, the slow temporal resolution of the technique may be inadequate to properly examine tonic and phasic Glu. Thus, our laboratory has developed an enzyme-based microelectrode array (MEA) with fast response time and low detection limits for Glu. We have modified the MEA design to allow for reliable measures in the brain of awake, freely moving mice. In this study, we chronically implanted the MEA in prefrontal cortex (PFC) or striatum (Str) of awake, freely moving C57BL/6 mice. We successfully measured Glu levels 7 days postimplantation without loss of MEA sensitivity. In addition, we determined resting (tonic) Glu levels to be 3.3 μM in the PFC and 5.0 μM in the Str. Resting Glu levels were subjected to pharmacological manipulation with tetrodotoxin (TTX) and dl-threo-β-hydroxyaspartate (THA). TTX significantly (p < 0.05) decreased resting Glu by 20%, whereas THA significantly (p < 0.05) increased resting Glu by 60%. Taken together, our data show that chronic recordings of tonic and phasic clearance of exogenously applied Glu can be carried out in awake mice for at least 7 days in vivo, allowing for longer term studies of Glu regulation.

1 September 2009 in Brain Research
Verified
Journal Article
Closed access
EHErin R. Hascup
Erin R. Hascup
SBSara Af Bjerkén
Sara Af Bjerkén
KHKevin N Hascup
Kevin N Hascup
FPFrancois Pomerleau
Francois Pomerleau
PHPeter Huettl
Peter Huettl
GGGreg A. Gerhardt
Greg A. Gerhardt

4 November 2009 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
XBXiaodong Bao
Xiaodong Bao
RPRanu Pal
Ranu Pal
KHKevin N Hascup
Kevin N Hascup
YWYongfu Wang
Yongfu Wang
WWWen-Tung Wang
Wen-Tung Wang
EMElias K. Michaelis
Elias K. Michaelis
The effects of lifelong, moderate excess release of glutamate (Glu) in the CNS have not been previously characterized. We created a transgenic (Tg) mouse model of lifelong excess synaptic Glu release in the CNS by introducing the gene for glutamate dehydrogenase 1 (Glud1) under the control of the neuron-specific enolase promoter.Glud1is, potentially, an important enzyme in the pathway of Glu synthesis in nerve terminals. Increased levels of GLUD protein and activity in CNS neurons of hemizygous Tg mice were associated with increases in thein vivorelease of Glu after neuronal depolarization in striatum and in the frequency and amplitude of miniature EPSCs in the CA1 region of the hippocampus. Despite overexpression ofGlud1in all neurons of the CNS, the Tg mice suffered neuronal losses in select brain regions (e.g., the CA1 but not the CA3 region). In vulnerable regions, Tg mice had decreases in MAP2A labeling of dendrites and in synaptophysin labeling of presynaptic terminals; the decreases in neuronal numbers and dendrite and presynaptic terminal labeling increased with advancing age. In addition, the Tg mice exhibited decreases in long-term potentiation of synaptic activity and in spine density in dendrites of CA1 neurons. Behaviorally, the Tg mice were significantly more resistant than wild-type mice to induction and duration of anesthesia produced by anesthetics that suppress Glu neurotransmission. TheGlud1mouse might be a useful model for the effects of lifelong excess synaptic Glu release on CNS neurons and for age-associated neurodegenerative processes.